Emerging Research in Prostate Cancer Imaging — September 2024

Currently in a phase I trial for solid prostate cancer tumors, the deoxycytidine kinase inhibitor TRE-515 garnered the fast track designation for possible combination use with Pluvicto in treating mCRPC.

In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.

Findings from the TRAILBLAZER-ALZ 6 study revealed a 41 percent reduction of the ARIA-E side effect at 24 weeks with the new dosing schedule for the anti-amyloid treatment donanemab-azbt.

An interview with two experts to discuss newly released guidance for using standardized MRI protocols for patients with this condition.

For patients with amyloid β (Aβ)-positive findings on positron emission tomography, higher educational attainment was associated with accelerated accumulation and spread of tau, according to new research.

In external testing, a model combining radiological complete response on breast MRI, nodal status and Ki-67 proliferation index yielded an 88 percent AUC for predicting pathologic complete response to neoadjuvant chemoimmunotherapy for patients with triple-negative breast cancer, according to new research.